Fortis Healthcare Ltd Valuation Shifts to Very Expensive Amid Strong Price Gains

Valuation Metrics Signal Elevated Price Levels

As of 12 Feb 2026, Fortis Healthcare’s price-to-earnings (P/E) ratio stands at a lofty 69.0, significantly above its industry peers and historical averages. This figure contrasts sharply with Narayana Hrudayalaya’s P/E of 44.78 and Global Health’s 54.08, both classified as expensive but notably lower than Fortis’s very expensive rating. The price-to-book value (P/BV) ratio of 7.37 further underscores the premium investors are willing to pay for Fortis shares, reflecting heightened expectations for future earnings growth or a scarcity premium in the hospital sector.

Other valuation multiples reinforce this elevated stance. The enterprise value to EBITDA (EV/EBITDA) ratio is 38.90, well above Narayana Hrudayalaya’s 27.48 and Global Health’s 33.12, signalling that the market is pricing Fortis at a substantial premium relative to its earnings before interest, taxes, depreciation, and amortisation. The EV to EBIT ratio of 49.81 and EV to sales of 8.57 also point to stretched valuations.

While the PEG ratio of 1.51 suggests some moderation when factoring in earnings growth, it remains elevated compared to typical market standards, indicating that growth expectations are priced in at a premium. Dividend yield remains minimal at 0.11%, reflecting the company’s reinvestment focus rather than income distribution.

Operational Efficiency and Returns

Fortis Healthcare’s return on capital employed (ROCE) and return on equity (ROE) stand at 11.89% and 10.68% respectively. These figures, while respectable, do not fully justify the steep valuation premiums. The ROCE indicates moderate efficiency in generating profits from capital investments, but the gap between valuation multiples and returns suggests investors are banking on sustained growth or strategic advantages.

Stock Performance Outpaces Benchmarks

Despite the valuation concerns, Fortis Healthcare’s stock has delivered impressive returns relative to the Sensex benchmark. Over the past year, the stock has surged 49.57%, dwarfing the Sensex’s 10.41% gain. The longer-term performance is even more striking, with five-year returns of 438.30% compared to the Sensex’s 63.46%, and a ten-year return of 492.53% versus the Sensex’s 267.00%. This outperformance reflects strong operational execution, sector tailwinds, and investor confidence in Fortis’s growth trajectory.

In the short term, the stock has also shown resilience, gaining 3.14% on the day to close at ₹920.50, with intraday highs touching ₹930.60. The 52-week trading range of ₹521.05 to ₹1,105.00 highlights significant volatility but also the stock’s capacity for substantial appreciation.

Mojo Score and Rating Revision

MarketsMOJO assigns Fortis Healthcare a Mojo Score of 64.0, reflecting a Hold rating as of 13 Jan 2025, a downgrade from the previous Buy grade. This revision aligns with the shift in valuation grading from expensive to very expensive, signalling caution to investors amid stretched price multiples. The market capitalisation grade remains low at 2, indicating that despite the company’s size, valuation concerns weigh heavily on the overall assessment.

Comparative Valuation: Fortis vs Peers

When analysing Fortis Healthcare alongside its hospital sector peers, the valuation premium becomes more evident. Narayana Hrudayalaya and Global Health, both rated expensive, trade at substantially lower P/E and EV/EBITDA multiples. Narayana’s PEG ratio of 4.66 and Global Health’s 4.55 suggest that while their valuations are high, Fortis’s PEG of 1.51 is comparatively more reasonable, albeit on a higher absolute P/E base. This dichotomy indicates that Fortis’s growth expectations are more moderate relative to its price, but the absolute valuation remains elevated.

Sector Dynamics and Growth Prospects

The hospital sector continues to benefit from rising healthcare demand, increasing insurance penetration, and technological advancements. Fortis Healthcare, with its extensive network and brand recognition, is well positioned to capitalise on these trends. However, the premium valuation implies that much of this growth potential is already factored into the share price, leaving limited margin for error.

Investors should weigh the company’s operational strengths and market leadership against the risk of valuation correction, especially if earnings growth fails to meet lofty expectations or if sector headwinds emerge.

Investor Takeaway: Valuation Caution Amid Strong Returns

Fortis Healthcare’s recent valuation upgrade to very expensive reflects a significant shift in price attractiveness. While the company’s fundamentals remain solid and its stock has outperformed the broader market handsomely over multiple time horizons, the elevated P/E and P/BV ratios suggest that investors are paying a premium that may limit upside potential in the near term.

Given the Hold rating and Mojo Score of 64.0, investors should approach Fortis shares with measured expectations, balancing the company’s growth prospects against the risk of valuation compression. Monitoring quarterly earnings, sector developments, and peer valuations will be critical to reassessing the stock’s attractiveness going forward.

In summary, Fortis Healthcare remains a key player in the hospital sector with strong operational credentials, but its current price levels warrant caution. The premium multiples highlight the importance of disciplined investing and the need to consider alternative opportunities within the healthcare space.

Unlock special upgrade rates for a limited period. Start Saving Now →